Description

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System Homozygote x Homozygote         (Female x Male)   01-MAR-06 Species laboratory mouse Generation N8+N3F4 (24-JAN-11) Generation Definitions   Donating Investigator Ronald M. Evans,   The Salk Inst for Biological Studies

Description
These mice possess loxP sites on either side of exons 1 and 2 of the targeted gene. Mice that are homozygous for this allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities.

When bred to a strain expressing Cre recombinase in adipose tissue (see Stock No. 005069 for example), this mutant mouse strain may be useful in studies of insulin resistance.

When bred to mice carrying Tg(Krt1-15-cre/PGR)22Cot (Stock No. 005249), Cre recombinase expression in the epithelial stem cells results in scarring alopecia.

When bred to mice carrying Tg(Tagln-cre)1Her (Stock No. 017491), Cre recombinase expression in vascular smooth muscle results in pulmonary arterial hypertension (PAH).

When bred to mice carrying Tg(Tek-cre)1Ywa (Stock No. 008863), Cre recombinase expression in the endothelial cells results in alterations in osteoclastogenesis, milk production (inflammatory milk), and hypertension.

When bred to mice carrying Tg(Tek-cre)12Flv (Stock No. 004128), Cre recombinase expression in the endothelial cells results in reduced vascular nitric oxide production and endothelial cell dysfunction.

When bred to mice carrying Tg(Lhb-cre)1Sac (Stock No. 009643), Cre recombinase expression in in pituitary cells that produce luteinizing hormone results in luteinizing hormone, a decrease in follicle-stimulating hormone and fertility defects.

When bred to mice carrying Tg(Cd4-cre)1Cwi (Stock No. 017336), Cre recombinase expression in in CD4 expressing T cells results in increased T-helper 17 cell differentiation.

Control Information

	Control
	000664 C57BL/6J
Considerations for Choosing Controls

Related Strains

Strains carrying other alleles of Pparg

008079	129S-Ppargtm2Yba/J
006142	B6.129S4-Ppargtm1Rev/J
008227	B6.129S4-Ppargtm3Yba/J

View Strains carrying other alleles of Pparg     (3 strains)

Additional Web Information

Introduction to Cre-lox technology

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI

- Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

Pulmonary Hypertension, Primary, 1; PPH1

- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Carotid Intimal Medial Thickness 1   (PPARG) Diabetes Mellitus, Noninsulin-Dependent; NIDDM   (PPARG) Lipodystrophy, Familial Partial, Type 3; FPLD3   (PPARG) Obesity   (PPARG)

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI

      assigned by genotype

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Pparg^tm2Rev/Pparg^tm2Rev Tg(Cd4-cre)1Cwi/?

        involves: 129S4/SvJae * C57BL/6 * DBA/2   (conditional)

• immune system phenotype
• abnormal T-helper 17 cell differentiation
  • increased   (MGI Ref ID J:153358)
  • accumulate in the CNS rather than the spleen in experimental autoimmune encephalitis   (MGI Ref ID J:153358)
• increased susceptibility to experimental autoimmune encephalomyelitis
  • earlier onset and aggravated disease course during the T-cell dependent phase   (MGI Ref ID J:153358)
  • difference from controls disappears after 15 days   (MGI Ref ID J:153358)
  • increased number of CD4+ T cells at the beginning of clinical disease (day 8) and at the disease peak (day 13) but not at day 18   (MGI Ref ID J:153358)
  • three fold increase in myelin oligodendrocyte glycoprotein specific T cells at disease peak   (MGI Ref ID J:153358)
• hematopoietic system phenotype
• abnormal T-helper 17 cell differentiation
  • increased   (MGI Ref ID J:153358)
  • accumulate in the CNS rather than the spleen in experimental autoimmune encephalitis   (MGI Ref ID J:153358)
• cellular phenotype
• abnormal T-helper 17 cell differentiation
  • increased   (MGI Ref ID J:153358)
  • accumulate in the CNS rather than the spleen in experimental autoimmune encephalitis   (MGI Ref ID J:153358)

Pparg^tm2Rev/Pparg^tm2Rev Tg(Krt1-15-cre/PGR)22Cot/?

        involves: 129S4/SvJae * C57BL/6 * SJL   (conditional)

• integument phenotype
• abnormal skin adnexa morphology   (MGI Ref ID J:150977)
• • abnormal coat appearance   (MGI Ref ID J:150977)
  • • matted coat
      • remaining hair becomes matted   (MGI Ref ID J:150977)
    • progressive hair loss
      • starting around 3 months and associated with increased hair loss   (MGI Ref ID J:150977)
  • abnormal hair follicle morphology
    • follicular ostia are dilated and plugged   (MGI Ref ID J:150977)
    • dystrophic hair follicles   (MGI Ref ID J:150977)
    • strands of fibrous connective tissue run perpendicular to the epidermis from dystrophic hair follicles   (MGI Ref ID J:150977)
  • abnormal skin sebaceous gland morphology
    • sometimes dystrophic and contiguous with follicular plugs   (MGI Ref ID J:150977)
  • sebaceous gland atrophy   (MGI Ref ID J:150977)
• abnormal skin morphology   (MGI Ref ID J:150977)
• • abnormal skin appearance   (MGI Ref ID J:150977)
  • • flaky skin
      • becomes flaky and crusty   (MGI Ref ID J:150977)
    • reddish skin
      • mild   (MGI Ref ID J:150977)
  • abnormal skin sebaceous gland morphology
    • sometimes dystrophic and contiguous with follicular plugs   (MGI Ref ID J:150977)
  • hyperkeratosis   (MGI Ref ID J:150977)
  • skin fibrosis
    • perifollicular fibrosis   (MGI Ref ID J:150977)
• skin inflammation
  • increased interstitial inflammation   (MGI Ref ID J:150977)
• behavior/neurological phenotype
• excessive scratching
  • associated with progressive hair loss   (MGI Ref ID J:150977)
• immune system phenotype
• skin inflammation
  • increased interstitial inflammation   (MGI Ref ID J:150977)
• endocrine/exocrine gland phenotype
• abnormal skin sebaceous gland morphology
  • sometimes dystrophic and contiguous with follicular plugs   (MGI Ref ID J:150977)
• sebaceous gland atrophy   (MGI Ref ID J:150977)

Pparg^tm2Rev/Pparg^tm2Rev Tg(Lhb-cre)1Sac/?

        involves: 129S4/SvJae * C57BL/6 * SJL   (conditional)

• reproductive system phenotype
• *normal* reproductive system phenotype
  • both males and females are fertile and produce litters at a normal rate   (MGI Ref ID J:170272)
  • estrus patterns are normal   (MGI Ref ID J:170272)
• • abnormal diestrus
    • diestrus levels of LH are elevated 3-fold   (MGI Ref ID J:170272)
  • decreased litter size   (MGI Ref ID J:170272)
• homeostasis/metabolism phenotype
• decreased circulating follicle stimulating hormone level
  • plasma levels are slightly but significantly reduced in males whereas levels are normal in females   (MGI Ref ID J:170272)
• increased luteinizing hormone level
  • diestrus levels are elevated 3-fold in females whereas male levels are normal   (MGI Ref ID J:170272)

Pparg^tm2Rev/Pparg^tm2Rev Tg(Tagln-cre)1Her/?

        involves: 129S4/SvJae * C57BL/6 * SJL   (conditional)

• cardiovascular system phenotype
• abnormal pulmonary artery morphology
  • increased muscularization of pulmonary arteries at the alveolar wall   (MGI Ref ID J:136168)
• heart right ventricle hypertrophy   (MGI Ref ID J:136168)
• increased right ventricle systolic pressure
  • elevated right ventricular systolic pressure   (MGI Ref ID J:136168)

Pparg^tm2Rev/Pparg^tm2Rev Tg(Tek-cre)12Flv/?

        B6.Cg-Pparg^tm2Rev Tg(Tek-cre)12Flv   (conditional)

• growth/size phenotype
• decreased body weight
  • about 5% less than controls   (MGI Ref ID J:154216)
• immune system phenotype
• enlarged spleen   (MGI Ref ID J:154216)
• hematopoietic system phenotype
• decreased hematocrit
  • slightly reduced hematocrit   (MGI Ref ID J:154216)
• enlarged spleen   (MGI Ref ID J:154216)
• cardiovascular system phenotype
• abnormal vascular endothelial cell physiology
  • reduced NO production in blood vessel endothelium   (MGI Ref ID J:154216)
• abnormal vasodilation
  • impaired endothelium dependent acetylcholine mediated relaxation of aortic rings   (MGI Ref ID J:154216)
• increased mean systemic arterial blood pressure
  • higher baseline pressure   (MGI Ref ID J:154216)
  • greater increase when challenged with angiotensin II   (MGI Ref ID J:154216)
• muscle phenotype
• abnormal vasodilation
  • impaired endothelium dependent acetylcholine mediated relaxation of aortic rings   (MGI Ref ID J:154216)
• impaired muscle relaxation
  • impaired endothelium dependent acetylcholine mediated relaxation of aortic rings   (MGI Ref ID J:154216)

Pparg^tm2Rev/Pparg^tm2Rev Tg(Tek-cre)1Ywa/?

        involves: 129S4/SvJae * C57BL/6 * SJL   (conditional)

• growth/size phenotype
• postnatal growth retardation
  • low body weight at weaning strictly dependent on maternal genotype   (MGI Ref ID J:123403)
  • body weight is normal in the first post natal week   (MGI Ref ID J:123403)
  • weight gain ceases completely at 10 days of age and does not resume until after weaning   (MGI Ref ID J:123403)
• integument phenotype
• abnormal hair cycle   (MGI Ref ID J:123403)
• • abnormal hair cycle anagen phase
    • new anagen phase does not begin until around 32 days   (MGI Ref ID J:123403)
  • abnormal hair shedding
    • formation of follicular cysts leading to shaft ejection at 20 days   (MGI Ref ID J:123403)
• abnormal skin adnexa morphology   (MGI Ref ID J:123403)
• • abnormal hair follicle morphology
    • formation of follicular cysts leading to shaft ejection at 20 days   (MGI Ref ID J:123403)
  • abnormal mammary gland alveolus morphology
    • fewer lobular alveolar structures in female mammary glands at day 4 of lactation   (MGI Ref ID J:123403)
    • more and larger adipocytes in female mammary glands at day 4 of lactation   (MGI Ref ID J:123403)
  • premature hair loss
    • near complete hair loss on the trunk strictly dependent on maternal genotype   (MGI Ref ID J:123403)
    • fostering on wild-type mothers corrects hair loss   (MGI Ref ID J:123403)
    • hair loss begins around 16 days of age and is complete on the trunk at about 18 days   (MGI Ref ID J:123403)
    • new hair growth begins 2-3 weeks after weaning and coat remains normal thereafter   (MGI Ref ID J:123403)
• skin inflammation
  • leukocyte infiltration around follicles between 20 and 32 days   (MGI Ref ID J:123403)
  • macrophage accumulate in the skin starting at 10 days   (MGI Ref ID J:123403)
• liver/biliary system phenotype
• pale liver
  • pale liver with increased lipid accumulation   (MGI Ref ID J:123403)
• cardiovascular system phenotype
• abnormal pulmonary artery morphology
  • increased number of muscularized distal pulmonary arteries   (MGI Ref ID J:155909)
• heart right ventricle hypertrophy
  • increased in normal air but similar to controls when both are under hypoxia   (MGI Ref ID J:155909)
• increased right ventricle systolic pressure
  • increased in normal air but similar to controls when both are under hypoxia   (MGI Ref ID J:155909)
  • less complete recovery from hypoxia than controls 4 weeks after return to normal air   (MGI Ref ID J:155909)
• homeostasis/metabolism phenotype
• increased triglyceride level
  • higher triglyceride levels   (MGI Ref ID J:155909)
  • higher triglyceride/HDL   (MGI Ref ID J:155909)
• skeleton phenotype
• abnormal bone structure
  • irregular, uneven bone structure   (MGI Ref ID J:130475)
• • abnormal bone marrow cavity morphology
    • decreased medullary cavity space   (MGI Ref ID J:130475)
  • abnormal osteoclast morphology   (MGI Ref ID J:130475)
  • • abnormal osteoclast differentiation
      • fail to produce osteoclasts in response to rosiglitazone treatment   (MGI Ref ID J:160910)
      • no increase in osteoclast numbers   (MGI Ref ID J:160910)
    • decreased osteoclast cell number
      • fewer osteoclasts in femur sections while osteoblast numbers are unchanged   (MGI Ref ID J:130475)
  • abnormal trabecular bone morphology   (MGI Ref ID J:130475)
  • • abnormal bone trabecula morphology
      • decreased trabecular separation   (MGI Ref ID J:130475)
      • no loss of trabecular bone after rosiglitazone treatment as occurs in controls   (MGI Ref ID J:160910)
    • • increased bone trabecula number   (MGI Ref ID J:130475)
    • increased trabecular bone thickness   (MGI Ref ID J:130475)
    • increased trabecular bone volume   (MGI Ref ID J:130475)
  • increased bone mineral density
    • 30-70% increase   (MGI Ref ID J:130475)
  • increased bone volume
    • bone volume/tissue volume ratio is 40-70% higher than controls in both the proximal and distal regions of the femur and tibia   (MGI Ref ID J:130475)
    • increased bone volume   (MGI Ref ID J:130475)
  • • increased trabecular bone volume   (MGI Ref ID J:130475)
• hematopoietic system phenotype
• *normal* hematopoietic system phenotype
  • white blood cell, red blood cell, and platelet counts remain normal   (MGI Ref ID J:130475)
• • abnormal bone marrow cell morphology/development   (MGI Ref ID J:130475)
  • • decreased bone marrow cell number
      • 35% decrease in cellularity   (MGI Ref ID J:130475)
      • both erythroid and granulocytic/monocytic   (MGI Ref ID J:130475)
      • hematopoietic stem cells reduced 56%   (MGI Ref ID J:130475)
  • abnormal osteoclast morphology   (MGI Ref ID J:130475)
  • • abnormal osteoclast differentiation
      • fail to produce osteoclasts in response to rosiglitazone treatment   (MGI Ref ID J:160910)
      • no increase in osteoclast numbers   (MGI Ref ID J:160910)
    • decreased osteoclast cell number
      • fewer osteoclasts in femur sections while osteoblast numbers are unchanged   (MGI Ref ID J:130475)
  • abnormal spleen morphology   (MGI Ref ID J:130475)
  • • abnormal splenocyte morphology
      • accumulation of megakaryocytes in the spleen   (MGI Ref ID J:130475)
    • • increased splenocyte number
        • 63% increase in spleen cellularity   (MGI Ref ID J:130475)
        • both erythroid and granulocytic/monocytic   (MGI Ref ID J:130475)
        • hematopoietic stem cells increased 275%   (MGI Ref ID J:130475)
    • enlarged spleen
      • spleen to body weight ratio increases 1.4-2 fold in adults and in 5 and 18 day old pups   (MGI Ref ID J:130475)
  • extramedullary hematopoiesis   (MGI Ref ID J:130475)
• immune system phenotype
• abnormal osteoclast morphology   (MGI Ref ID J:130475)
• • abnormal osteoclast differentiation
    • fail to produce osteoclasts in response to rosiglitazone treatment   (MGI Ref ID J:160910)
    • no increase in osteoclast numbers   (MGI Ref ID J:160910)
  • decreased osteoclast cell number
    • fewer osteoclasts in femur sections while osteoblast numbers are unchanged   (MGI Ref ID J:130475)
• abnormal spleen morphology   (MGI Ref ID J:130475)
• • abnormal splenocyte morphology
    • accumulation of megakaryocytes in the spleen   (MGI Ref ID J:130475)
  • • increased splenocyte number
      • 63% increase in spleen cellularity   (MGI Ref ID J:130475)
      • both erythroid and granulocytic/monocytic   (MGI Ref ID J:130475)
      • hematopoietic stem cells increased 275%   (MGI Ref ID J:130475)
  • enlarged spleen
    • spleen to body weight ratio increases 1.4-2 fold in adults and in 5 and 18 day old pups   (MGI Ref ID J:130475)
• skin inflammation
  • leukocyte infiltration around follicles between 20 and 32 days   (MGI Ref ID J:123403)
  • macrophage accumulate in the skin starting at 10 days   (MGI Ref ID J:123403)
• cellular phenotype
• abnormal osteoclast differentiation
  • fail to produce osteoclasts in response to rosiglitazone treatment   (MGI Ref ID J:160910)
  • no increase in osteoclast numbers   (MGI Ref ID J:160910)
• endocrine/exocrine gland phenotype
• abnormal mammary gland alveolus morphology
  • fewer lobular alveolar structures in female mammary glands at day 4 of lactation   (MGI Ref ID J:123403)
  • more and larger adipocytes in female mammary glands at day 4 of lactation   (MGI Ref ID J:123403)

The following phenotype relates to a compound genotype created using this strain.
Contact JAX^® Services jaxservices@jax.org for customized breeding options.

Pparg^tm2Rev/Pparg^tm2Rev Tg(Fabp4-cre)1Rev/?

        involves: 129S4/SvJae * C57BL/6   (conditional)

• adipose tissue phenotype
• abnormal brown adipose tissue morphology
  • vacuole form sometimes like white adipose cells rather than typical brown fat cells   (MGI Ref ID J:88210)
• • abnormal brown fat cell size   (MGI Ref ID J:88210)
  • • increased brown fat cell size
      • cells are larger and variable in size   (MGI Ref ID J:88210)
  • decreased brown adipose tissue amount
    • brown adipose tissue mass reduced more than 70% by 6 months of age   (MGI Ref ID J:88210)
  • decreased brown fat cell number
    • cell numbers reduced more than 95%   (MGI Ref ID J:88210)
• abnormal white adipose tissue amount
  • cell loss greater than 80%   (MGI Ref ID J:88210)
• decreased interscapular fat pad weight
  • diminution of interscapular fat pads detectable by 4-6 weeks   (MGI Ref ID J:88210)
• increased white fat cell size
  • more than 50% of white adipocytes are highly hypertrophic   (MGI Ref ID J:88210)
• growth/size phenotype
• slow postnatal weight gain
  • weight gain on a high fat diet is decreased   (MGI Ref ID J:88210)
• homeostasis/metabolism phenotype
• increased circulating insulin level
  • insulin levels are increased   (MGI Ref ID J:88210)
• insulin resistance
  • insulin became less efficient at suppressing glucose production   (MGI Ref ID J:88210)
• liver/biliary system phenotype
• enlarged liver
  • hepatomegaly eventually develops as well   (MGI Ref ID J:88210)
• hepatic steatosis
  • livers were beginning to be steatotic at 6 months of age   (MGI Ref ID J:88210)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Research Tools
Cre-lox System
      loxP-flanked Sequences
Diabetes and Obesity Research
      loxP
Metabolism Research

Pparg^tm2Rev related

Research Tools
Cardiovascular Research
      Cre-lox System
Diabetes and Obesity Research
      loxP

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol		Ppargtm2Rev
Allele Name		targeted mutation 2, Ronald M Evans
Allele Type		Targeted (Floxed/Frt)
Common Name(s)		PPARgammaf; PPARgammafl; Ppargflox; gf;
Mutation Made By		Yaacov Barak,   University of Pittsburgh
Strain of Origin		129S4/SvJae
ES Cell Line Name		J1
ES Cell Line Strain		129S4/SvJae
Gene Symbol and Name		Pparg, peroxisome proliferator activated receptor gamma
Chromosome		6
Gene Common Name(s)		CIMT1; GLM1; NR1C3; PPAR-gamma; PPARG1; PPARG2; PPARgamma; PPARgamma2; Ppar-gamma2;
Molecular Note		A single loxP site was introduced upstream of exon 1 and a floxed neomycin cassette was inserted downstream of exon 2. The neomycin gene was excised from correctly targeted ES cells by transient transfection with a Cre expression plasmid. [MGI Ref ID J:88210]

Genotyping

Genotyping Information

Genotyping Protocols

Pparg^tm2Rev, Standard PCR

Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

He W; Barak Y; Hevener A; Olson P; Liao D; Le J; Nelson M; Ong E; Olefsky JM; Evans RM. 2003. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100(26):15712-7. [PubMed: 14660788]  [MGI Ref ID J:88210]

Additional References

Pparg^tm2Rev related

Avagyan S; Aguilo F; Kamezaki K; Snoeck HW. 2011. Quantitative trait mapping reveals a regulatory axis involving peroxisome proliferator-activated receptors, PRDM16, transforming growth factor-beta2 and FLT3 in hematopoiesis. Blood 118(23):6078-86. [PubMed: 21967974]  [MGI Ref ID J:179097]

Chang L; Villacorta L; Zhang J; Garcia-Barrio MT; Yang K; Hamblin M; Whitesall SE; D'Alecy LG; Chen YE. 2009. Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-gamma deletion leads to hypotension. Circulation 119(16):2161-9. [PubMed: 19364979]  [MGI Ref ID J:166495]

Davies BS; Waki H; Beigneux AP; Farber E; Weinstein MM; Wilpitz DC; Tai LJ; Evans RM; Fong LG; Tontonoz P; Young SG. 2008. The expression of GHIBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-gamma. Mol Endocrinol 22(11):2496-504. [PubMed: 18787041]  [MGI Ref ID J:141250]

Gautier EL; Chow A; Spanbroek R; Marcelin G; Greter M; Jakubzick C; Bogunovic M; Leboeuf M; van Rooijen N; Habenicht AJ; Merad M; Randolph GJ. 2012. Systemic analysis of PPARgamma in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity. J Immunol 189(5):2614-24. [PubMed: 22855714]  [MGI Ref ID J:189849]

Gomez-Arroyo J; Saleem SJ; Mizuno S; Syed AA; Bogaard HJ; Abbate A; Taraseviciene-Stewart L; Sung Y; Kraskauskas D; Farkas D; Conrad DH; Nicolls MR; Voelkel NF. 2012. A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. Am J Physiol Lung Cell Mol Physiol 302(10):L977-91. [PubMed: 22307907]  [MGI Ref ID J:190182]

Guignabert C; Alvira CM; Alastalo TP; Sawada H; Hansmann G; Zhao M; Wang L; El-Bizri N; Rabinovitch M. 2009. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol 297(6):L1082-90. [PubMed: 19801450]  [MGI Ref ID J:155909]

Hamblin M; Chang L; Zhang H; Yang K; Zhang J; Chen YE. 2011. Vascular smooth muscle cell peroxisome proliferator-activated receptor-gamma mediates pioglitazone-reduced vascular lesion formation. Arterioscler Thromb Vasc Biol 31(2):352-9. [PubMed: 21088248]  [MGI Ref ID J:184182]

Hansmann G; de Jesus Perez VA; Alastalo TP; Alvira CM; Guignabert C; Bekker JM; Schellong S; Urashima T; Wang L; Morrell NW; Rabinovitch M. 2008. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 118(5):1846-57. [PubMed: 18382765]  [MGI Ref ID J:136168]

Jonker JW; Suh JM; Atkins AR; Ahmadian M; Li P; Whyte J; He M; Juguilon H; Yin YQ; Phillips CT; Yu RT; Olefsky JM; Henry RR; Downes M; Evans RM. 2012. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 485(7398):391-4. [PubMed: 22522926]  [MGI Ref ID J:183996]

Karnik P; Tekeste Z; McCormick TS; Gilliam AC; Price VH; Cooper KD; Mirmirani P. 2009. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 129(5):1243-57. [PubMed: 19052558]  [MGI Ref ID J:150977]

Kiss E; Popovic ZV; Bedke J; Adams J; Bonrouhi M; Babelova A; Schmidt C; Edenhofer F; Zschiedrich I; Domhan S; Abdollahi A; Schafer L; Gretz N; Porubsky S; Grone HJ. 2010. Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage. Am J Pathol 176(5):2150-62. [PubMed: 20363918]  [MGI Ref ID J:160750]

Kleinhenz JM; Kleinhenz DJ; You S; Ritzenthaler JD; Hansen JM; Archer DR; Sutliff RL; Hart CM. 2009. Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production. Am J Physiol Heart Circ Physiol 297(5):H1647-54. [PubMed: 19666848]  [MGI Ref ID J:154216]

Klotz L; Burgdorf S; Dani I; Saijo K; Flossdorf J; Hucke S; Alferink J; Novak N; Beyer M; Mayer G; Langhans B; Klockgether T; Waisman A; Eberl G; Schultze J; Famulok M; Kolanus W; Glass C; Kurts C; Knolle PA. 2009. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J Exp Med 206(10):2079-89. [PubMed: 19737866]  [MGI Ref ID J:153358]

Klotz L; Dani I; Edenhofer F; Nolden L; Evert B; Paul B; Kolanus W; Klockgether T; Knolle P; Diehl L. 2007. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J Immunol 178(4):2122-31. [PubMed: 17277116]  [MGI Ref ID J:143994]

Legutko A; Marichal T; Fievez L; Bedoret D; Mayer A; de Vries H; Klotz L; Drion PV; Heirman C; Cataldo D; Louis R; Thielemans K; Andris F; Leo O; Lekeux P; Desmet CJ; Bureau F. 2011. Sirtuin 1 promotes Th2 responses and airway allergy by repressing peroxisome proliferator-activated receptor-gamma activity in dendritic cells. J Immunol 187(9):4517-29. [PubMed: 21948987]  [MGI Ref ID J:179447]

Li H; Sorenson AL; Poczobutt J; Amin J; Joyal T; Sullivan T; Crossno JT Jr; Weiser-Evans MC; Nemenoff RA. 2011. Activation of PPARgamma in myeloid cells promotes lung cancer progression and metastasis. PLoS One 6(12):e28133. [PubMed: 22145026]  [MGI Ref ID J:182274]

Luo W; Cao J; Li J; He W. 2008. Adipose tissue-specific PPARgamma deficiency increases resistance to oxidative stress. Exp Gerontol 43(3):154-63. [PubMed: 18083318]  [MGI Ref ID J:132506]

Moran-Salvador E; Lopez-Parra M; Garcia-Alonso V; Titos E; Martinez-Clemente M; Gonzalez-Periz A; Lopez-Vicario C; Barak Y; Arroyo V; Claria J. 2011. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 25(8):2538-50. [PubMed: 21507897]  [MGI Ref ID J:196866]

Necela BM; Su W; Thompson EA. 2008. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages. Immunology 125(3):344-58. [PubMed: 18422969]  [MGI Ref ID J:144451]

Sahu RP; Dasilva SC; Rashid B; Martel KC; Jernigan D; Mehta SR; Mohamed DR; Rezania S; Bradish JR; Armstrong AB; Warren S; Konger RL. 2012. Mice lacking epidermal PPARgamma exhibit a marked augmentation in photocarcinogenesis associated with increased UVB-induced apoptosis, inflammation and barrier dysfunction. Int J Cancer 131(7):E1055-66. [PubMed: 22467332]  [MGI Ref ID J:186081]

Sharma S; Sharma PM; Mistry DS; Chang RJ; Olefsky JM; Mellon PL; Webster NJ. 2011. PPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice. Biol Reprod 84(3):466-75. [PubMed: 21076077]  [MGI Ref ID J:170272]

Subramanian V; Golledge J; Ijaz T; Bruemmer D; Daugherty A. 2010. Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}. Circ Res 107(8):953-8. [PubMed: 20798360]  [MGI Ref ID J:178193]

Vasheghani F; Monemdjou R; Fahmi H; Zhang Y; Perez G; Blati M; St-Arnaud R; Pelletier JP; Beier F; Martel-Pelletier J; Kapoor M. 2013. Adult cartilage-specific peroxisome proliferator-activated receptor gamma knockout mice exhibit the spontaneous osteoarthritis phenotype. Am J Pathol 182(4):1099-106. [PubMed: 23375622]  [MGI Ref ID J:194317]

Wan Y; Chong LW; Evans RM. 2007. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13(12):1496-503. [PubMed: 18059282]  [MGI Ref ID J:130475]

Wan Y; Saghatelian A; Chong LW; Zhang CL; Cravatt BF; Evans RM. 2007. Maternal PPAR{gamma} protects nursing neonates by suppressing the production of inflammatory milk. Genes Dev 21(15):1895-908. [PubMed: 17652179]  [MGI Ref ID J:123403]

Wei W; Wang X; Yang M; Smith LC; Dechow PC; Wan Y. 2010. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11(6):503-16. [PubMed: 20519122]  [MGI Ref ID J:160910]

Yang L; Chan CC; Kwon OS; Liu S; McGhee J; Stimpson SA; Chen LZ; Harrington WW; Symonds WT; Rockey DC. 2006. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291(5):G902-11. [PubMed: 16798724]  [MGI Ref ID J:116893]

Zhao X; Strong R; Zhang J; Sun G; Tsien JZ; Cui Z; Grotta JC; Aronowski J. 2009. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci 29(19):6186-95. [PubMed: 19439596]  [MGI Ref ID J:148757]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Room Number           AX12

Colony Maintenance

Mating System	Homozygote x Homozygote         (Female x Male)   01-MAR-06
Diet Information	LabDiet® 5K52/5K67

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

General Supply Notes

• Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

	Control
	000664 C57BL/6J
Considerations for Choosing Controls
Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering Information
JAX^® Mice
Surgical and Preconditioning Services
JAX^® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license.

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.